Comparative Pharmacology
Head-to-head clinical analysis: TAZICEF versus VELOSEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAZICEF versus VELOSEF.
TAZICEF vs VELOSEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftazidime is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3, leading to cell lysis and death.
Cephalosporin antibiotic; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
2 g intravenously every 8 hours for serious infections; 1 g intravenously every 8 hours for uncomplicated infections.
250-500 mg orally every 6 hours or 1-2 g intramuscularly/intravenously every 6-12 hours for moderate to severe infections.
None Documented
None Documented
2 hours (prolonged to 4-12 hours in renal impairment; anuria: 20-30 hours).
1-2 hours (normal renal function); prolonged to 10-30 hours in severe renal impairment (CrCl <10 mL/min)
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal <10%.
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); small biliary/fecal (5-10%)
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic